Anticancer and antioxidative effects of micronized zeolite clinoptilolite.
BACKGROUND
Treatment of cancer-bearing mice and dogs with micronized zeolite clinoptilolite (MZ) led to improvement of the overall health status, prolongation of life span and decrease of tumor size in some cases. It also reduced lipid peroxidation in the liver of mice.


METHODS
The experiments were performed on various tumor cell cultures and tumor-bearing animals. Immunohistochemistry was used to analyze if MZ could interfere with Doxorubicin-induced lipid peroxidation and consequential production of 4-hydroxynonenal (HNE).


RESULTS
MZ reduced the metabolic rate of cancer cells and increased binding of HNE to albumin in vitro. It selectively reduced generation of HNE in vivo in tumor stroma after Doxorubicin treatment leaving onset of lipid peroxidation intact in malignant cells. Combined treatment with Doxorubicin and MZ resulted in strong reduction of the pulmonary metastasis count increasing anticancer effects of Doxorubicin.


CONCLUSIONS
Interference of MZ with lipid peroxidation might explain some of the beneficial effects of this particular zeolite in combined cancer therapy.
Zarkovic
Neven
N
Ruder Boskovic Institute, Division of Molecular Medicine, Bijenicka 54, HR-10000 Zagreb, Croatia.
Zarkovic
Kamelija
K
Kralj
Marijeta
M
Borovic
Suzana
S
Sabolovic
Senka
S
Blazi
Marija Poljak
MP
Cipak
Ana
A
Pavelic
Kresimir
K
D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary; D000447:Aldehydes / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000473:pathology; D002277:Carcinoma / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D003110:Colonic Neoplasms / Q000473:pathology; D004317:Doxorubicin / Q000008:administration & dosage / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor; D006367:HeLa Cells / Q000187:drug effects; D006801:Humans; D007822:Laryngeal Neoplasms / Q000473:pathology; D015227:Lipid Peroxidation / Q000187:drug effects*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000517:prevention & control / Q000556:secondary; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000473:pathology; D051379:Mice; D008808:Mice, Inbred CBA; D018384:Oxidative Stress; D010190:Pancreatic Neoplasms / Q000473:pathology; D010316:Particle Size; D011485:Protein Binding / Q000187:drug effects; D017382:Reactive Oxygen Species; D015290:Second Messenger Systems; D012709:Serum Albumin / Q000378:metabolism; D014961:X-Ray Diffraction; D017641:Zeolites / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D000447:Aldehydes; D000970:Antineoplastic Agents; D000975:Antioxidants; D017382:Reactive Oxygen Species; D012709:Serum Albumin; C083175:clinoptilolite; D017641:Zeolites; D004317:Doxorubicin; C027576:4-hydroxy-2-nonenal